FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030666284> ?p ?o ?g. }

• W3030666284 endingPage "2542" @default.
• W3030666284 startingPage "2530" @default.
• W3030666284 abstract "PURPOSE Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non–small-cell lung cancer (NSCLC). We present safety and patient-reported outcomes (PROs) to provide additional information on the relative impact of adding atezolizumab to chemotherapy with and without bevacizumab in nonsquamous NSCLC. METHODS Patients were randomly assigned to receive atezolizumab, carboplatin, and paclitaxel (ACP), ABCP, or BCP. Coprimary end points were overall survival and investigator-assessed progression-free survival. The incidence, nature, and severity of adverse events (AEs) were assessed. PROs, a secondary end point, were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-Lung Cancer 13. RESULTS Overall, 400 (ACP), 393 (ABCP), and 394 (BCP) patients were safety evaluable (ie, intention-to-treat population that received one or more doses of any study treatment). More patients had grade 3/4 treatment-related AEs during the induction versus maintenance phase (ACP, 40.5% v 8.2%; ABCP, 48.6% v 21.2%; BCP, 44.7% v 11.1%). During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively. During maintenance, SAE incidences were 20.0%, 26.3%, and 13.0%, respectively. Completion rates of the PRO questionnaires were > 88% at baseline and remained ≥ 70% throughout most study visits. Across arms, patients on average reported no clinically meaningful worsening of global health status or physical functioning scores through cycle 13. Patients across arms rated common symptoms with chemotherapy and immunotherapy similarly. CONCLUSION ABCP seems tolerable and manageable versus ACP and BCP in first-line nonsquamous NSCLC. Treatment tolerability differed between induction and maintenance phases across treatment arms. PROs reflect a minimal treatment burden (eg, health-related quality of life, symptoms) with each regimen." @default.
• W3030666284 created "2020-06-05" @default.
• W3030666284 creator A5001646287 @default.
• W3030666284 creator A5002934898 @default.
• W3030666284 creator A5017742334 @default.
• W3030666284 creator A5025814906 @default.
• W3030666284 creator A5040589443 @default.
• W3030666284 creator A5042110139 @default.
• W3030666284 creator A5042546997 @default.
• W3030666284 creator A5042678435 @default.
• W3030666284 creator A5043421969 @default.
• W3030666284 creator A5044032162 @default.
• W3030666284 creator A5044171245 @default.
• W3030666284 creator A5046728958 @default.
• W3030666284 creator A5051697945 @default.
• W3030666284 creator A5062778583 @default.
• W3030666284 creator A5067155382 @default.
• W3030666284 creator A5075562434 @default.
• W3030666284 creator A5078629724 @default.
• W3030666284 creator A5080258524 @default.
• W3030666284 creator A5083786421 @default.
• W3030666284 date "2020-08-01" @default.
• W3030666284 modified "2023-10-14" @default.
• W3030666284 title "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer" @default.
• W3030666284 cites W1947168884 @default.
• W3030666284 cites W2043176665 @default.
• W3030666284 cites W2070309415 @default.
• W3030666284 cites W2090295250 @default.
• W3030666284 cites W2093412094 @default.
• W3030666284 cites W2104347254 @default.
• W3030666284 cites W2109567704 @default.
• W3030666284 cites W2122515395 @default.
• W3030666284 cites W2144239121 @default.
• W3030666284 cites W2145835533 @default.
• W3030666284 cites W2156353875 @default.
• W3030666284 cites W2163351155 @default.
• W3030666284 cites W2167571044 @default.
• W3030666284 cites W2198093519 @default.
• W3030666284 cites W2413971556 @default.
• W3030666284 cites W2523715715 @default.
• W3030666284 cites W2527905628 @default.
• W3030666284 cites W2567564314 @default.
• W3030666284 cites W2753603515 @default.
• W3030666284 cites W2756887587 @default.
• W3030666284 cites W2775052471 @default.
• W3030666284 cites W2775356055 @default.
• W3030666284 cites W2796582438 @default.
• W3030666284 cites W2805354595 @default.
• W3030666284 cites W2806313789 @default.
• W3030666284 cites W2904103135 @default.
• W3030666284 cites W2924289105 @default.
• W3030666284 cites W2925446385 @default.
• W3030666284 cites W4210992155 @default.
• W3030666284 cites W81256119 @default.
• W3030666284 doi "https://doi.org/10.1200/jco.19.03158" @default.
• W3030666284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7392741" @default.
• W3030666284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32459597" @default.
• W3030666284 hasPublicationYear "2020" @default.
• W3030666284 type Work @default.
• W3030666284 sameAs 3030666284 @default.
• W3030666284 citedByCount "39" @default.
• W3030666284 countsByYear W30306662842020 @default.
• W3030666284 countsByYear W30306662842021 @default.
• W3030666284 countsByYear W30306662842022 @default.
• W3030666284 countsByYear W30306662842023 @default.
• W3030666284 crossrefType "journal-article" @default.
• W3030666284 hasAuthorship W3030666284A5001646287 @default.
• W3030666284 hasAuthorship W3030666284A5002934898 @default.
• W3030666284 hasAuthorship W3030666284A5017742334 @default.
• W3030666284 hasAuthorship W3030666284A5025814906 @default.
• W3030666284 hasAuthorship W3030666284A5040589443 @default.
• W3030666284 hasAuthorship W3030666284A5042110139 @default.
• W3030666284 hasAuthorship W3030666284A5042546997 @default.
• W3030666284 hasAuthorship W3030666284A5042678435 @default.
• W3030666284 hasAuthorship W3030666284A5043421969 @default.
• W3030666284 hasAuthorship W3030666284A5044032162 @default.
• W3030666284 hasAuthorship W3030666284A5044171245 @default.
• W3030666284 hasAuthorship W3030666284A5046728958 @default.
• W3030666284 hasAuthorship W3030666284A5051697945 @default.
• W3030666284 hasAuthorship W3030666284A5062778583 @default.
• W3030666284 hasAuthorship W3030666284A5067155382 @default.
• W3030666284 hasAuthorship W3030666284A5075562434 @default.
• W3030666284 hasAuthorship W3030666284A5078629724 @default.
• W3030666284 hasAuthorship W3030666284A5080258524 @default.
• W3030666284 hasAuthorship W3030666284A5083786421 @default.
• W3030666284 hasBestOaLocation W30306662841 @default.
• W3030666284 hasConcept C121608353 @default.
• W3030666284 hasConcept C126322002 @default.
• W3030666284 hasConcept C141071460 @default.
• W3030666284 hasConcept C143998085 @default.
• W3030666284 hasConcept C197934379 @default.
• W3030666284 hasConcept C203092338 @default.
• W3030666284 hasConcept C2775949291 @default.
• W3030666284 hasConcept C2776256026 @default.
• W3030666284 hasConcept C2776694085 @default.
• W3030666284 hasConcept C2777292972 @default.
• W3030666284 hasConcept C2777701055 @default.
• W3030666284 hasConcept C2777802072 @default.

• next